CLAY VEURINK: Open Payments
NPI 1780390427 · SPARTA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,529 in 140 payments from 17 companies in 2025. Trend: 2023 $113 · 2024 $637 · 2025 $2,529
Food & beverage: $2,405Education: $124
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 21 | $487 |
| Otsuka America Pharmaceutical, Inc. | 24 | $335 |
| Alkermes, Inc. | 19 | $306 |
| Neurocrine BioSciences, Inc. | 12 | $298 |
| ABBVIE INC. | 17 | $252 |
| Teva Pharmaceuticals USA, Inc. | 16 | $242 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $190 |
| ViiV Healthcare Company | 4 | $106 |
| Janssen Pharmaceuticals, Inc | 4 | $78 |
| Vanda Pharmaceuticals Inc. | 2 | $68 |
Products named: COBENFY, ARISTADA, INGREZZA, VRAYLAR, CAPLYTA, REXULTI, ABILIFY ASIMTUFII, APRETUDE.
Industry payments across MO — which companies pay providers there.
